AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
191.44
-7.57 (-3.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close199.01
Open197.89
Bid191.40 x 200
Ask191.75 x 100
Day's Range191.06 - 198.39
52 Week Range163.31 - 210.19
Volume3,143,027
Avg. Volume2,931,676
Market Cap121.989B
Beta (3Y Monthly)1.36
PE Ratio (TTM)59.68
EPS (TTM)3.21
Earnings DateJan 30, 2019 - Feb 4, 2019
Forward Dividend & Yield5.28 (2.74%)
Ex-Dividend Date2018-11-15
1y Target Est204.80
Trade prices are not sourced from all markets
  • Amgen Increases Quarterly Dividend
    GuruFocus.com11 hours ago

    Amgen Increases Quarterly Dividend

    Amgen Inc. (AMGN) has informed the market Friday after closing bell that the board of directors of the company has authorized the payment of a quarterly dividend for the first trimester of fiscal 2019. The company will pay shareholders a cash dividend of $1.45 per share, reflecting a 9.8% increase from the previous one. Warning! GuruFocus has detected 2 Warning Signs with AABA.

  • Is AbbVie Inc (ABBV) A Good Stock To Buy?
    Insider Monkeyyesterday

    Is AbbVie Inc (ABBV) A Good Stock To Buy?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]

  • Is Amgen, Inc. (AMGN) A Good Stock To Buy?
    Insider Monkey2 days ago

    Is Amgen, Inc. (AMGN) A Good Stock To Buy?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • MarketWatch2 days ago

    Amgen raises dividend by 10%

    Amgen Inc. said late Friday its board of directors has declared a dividend of $1.45 a share for the first quarter of 2019. The dividend is payable March 8 to shareholders of record on Feb. 15. That represents a 10% increase from what Amgen paid in each of the previous four quarters. Shares of Amgen rose 0.2% in the extended session Friday after ending the regular trading day down 3.8%.

  • PR Newswire2 days ago

    Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

    THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

  • Investing.com2 days ago

    Amgen Falls 3%

    Investing.com - Amgen (NASDAQ:AMGN) fell by 3.14% to trade at $192.76 by 12:33 (17:33 GMT) on Friday on the NASDAQ exchange.

  • The Wall Street Journal3 days ago

    [$$] Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices?

    Critics of high drug prices are launching a new line of attack against manufacturers of the medicines, faulting the firms for using savings from the tax overhaul to buy back shares rather than lower prices. The attacks began in October, when more than a dozen Democrats in the House of Representatives sent letters to five big pharmaceutical companies saying they had benefited from recent tax cuts but kept charging high prices. The letters singled out certain drugs whose list prices had increased and asked their manufacturers for details about price changes and the costs of research and advertising.

  • 10 Stocks to Buy When the Yield Curve Inverts
    InvestorPlace5 days ago

    10 Stocks to Buy When the Yield Curve Inverts

    Will the yield curve invert, with short-term interest rates pushing their way above long-term interest rates … a relatively rare scenario that’s all too often associated with a troubled economy? A true inverted yield curve has not happened yet, but as of right now we’re as close to an inverted yield curve as we’ve been in a decade. Translation: It sure couldn’t hurt to go ahead and make plans for an inverted yield curve, just in case that’s how things take shape.

  • Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China
    Zacks5 days ago

    Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China

    This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.

  • Roche's Tecentriq Combination Gets Priority Review by FDA
    Zacks5 days ago

    Roche's Tecentriq Combination Gets Priority Review by FDA

    The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.

  • Can Celgene and bluebird bio Survive a Two-Pronged Attack?
    Motley Fool5 days ago

    Can Celgene and bluebird bio Survive a Two-Pronged Attack?

    A promising program these partners are working on is under assault from two different directions.

  • Amgen's BiTE Immunotherapies Show Promise in Early Studies
    Zacks5 days ago

    Amgen's BiTE Immunotherapies Show Promise in Early Studies

    Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA

  • Ajovy Is a New Growth Driver for Teva Pharmaceutical
    Market Realist6 days ago

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Benzinga6 days ago

    The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...

  • Reuters6 days ago

    Amgen antibody shows promise in myeloma trial, gets FDA fast track

    Amgen Inc (AMGN.O), updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Haematology (ASH). Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.

  • Reuters6 days ago

    Amgen antibody shows promise in myeloma trial, gets FDA fast track

    Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.

  • PR Newswire6 days ago

    Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

    THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in patients with relapsed and/or refractory multiple myeloma and relapsed or refractory acute myeloid leukemia (AML), respectively.

  • PR Newswire6 days ago

    Amgen To Present At The Citi Global Healthcare Conference

    THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday , Dec. 6, 2018, in New York City . Elliott M. ...

  • Investing.com6 days ago

    Amgen Falls 3%

    Investing.com - Amgen (NASDAQ:AMGN) fell by 3.03% to trade at $201.94 by 13:35 (18:35 GMT) on Monday on the NASDAQ exchange.

  • Could Amgen Inc’s (NASDAQ:AMGN) Investor Composition Influence The Stock Price?
    Simply Wall St.7 days ago

    Could Amgen Inc’s (NASDAQ:AMGN) Investor Composition Influence The Stock Price?

    Every investor in Amgen Inc (NASDAQ:AMGN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...

  • AbbVie Settles With Pfizer for Humira Biosimilar in U.S.
    Zacks7 days ago

    AbbVie Settles With Pfizer for Humira Biosimilar in U.S.

    AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November

  • FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate
    Zacks7 days ago

    FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate

    The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.

  • Benzinga7 days ago

    The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

    Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...

  • Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar
    Investor's Business Daily9 days ago

    Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar

    Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.